Australia markets close in 29 minutes

    +50.40 (+0.69%)
  • ASX 200

    +49.70 (+0.71%)

    +0.0020 (+0.26%)
  • OIL

    +0.27 (+0.41%)
  • GOLD

    +3.40 (+0.18%)

    +3,075.38 (+5.57%)
  • CMC Crypto 200

    +65.70 (+5.48%)

    +0.0008 (+0.13%)

    -0.0007 (-0.06%)
  • NZX 50

    +18.15 (+0.15%)

    -80.21 (-0.60%)
  • FTSE

    -10.76 (-0.15%)
  • Dow Jones

    -54.34 (-0.16%)
  • DAX

    -20.02 (-0.13%)
  • Hang Seng

    +361.53 (+1.28%)
  • NIKKEI 225

    +648.47 (+2.33%)

Cancer Biologics Market Report 2021-2031

·3-min read

Forecasts by Treatment (Chemotherapy, Targeted Therapy, Immunotherapy, Hormonal Therapy, Others), by Indication (Breast Cancer, Cervical Cancer, Colon and Rectal Cancer, Gastric Cancer, Lung Cancer, Ovarian Cancer, Renal Cell Cancer, Melanoma), by Biologic Drugs (Bevacizumab, Trastuzumab, Trastuzumab Emtansine, Pertuzumab, Rituximab, Cetuximab, Panitumumab, Ramucirumab, Necitumumab, Pembrolizumab, Atezolizumab, Durvalumab, Nivolumab, Ipilimumab), by End-user (Hospitals, Specialty Clinics, Cancer and Radiation Therapy Centers) AND Regional and Leading National Market Analysis PLUS Analysis of Leading Cancer Biologics Companies AND COVID-19 Recovery Scenarios

New York, April 15, 2021 (GLOBE NEWSWIRE) -- announces the release of the report "Cancer Biologics Market Report 2021-2031" -

This report is intended to provide an in-depth analysis of the latest trends prevailing in the cancer biologics market and its growth and development in the next decade. The changing demographics of the world population, increasing cancer prevalence, developing healthcare infrastructure, emerging economies, consumer spending behaviour, per capita income, macroeconomic factors, rising GDPs, and the reformation in laws and regulations are trend setting factors, which will affect the market.
Why Cancer Biologics Market is Growing?
The main drivers for the growth include technological advancements in the development of novel biomarkers, rising preference for minimally or less invasive surgeries, increasing cancer awareness leading to growth in cancer cases, and growing disposable income in emerging economies. Moreover, rising number of pre-screening programs for cancer detection using liquid biopsy are expected to provide new market opportunities for cancer biologics in near future.
What are the Market Driving Factors?
. Rising Cancer Prevalence Worldwide
. Increasing Ageing Population in Developed as well as Developing Economies
Key Challenges for Cancer Biologics Market
. Shortage of Skilled Workforce in the Biopharmaceutical Industry
. High Cost Associated with Biopharmaceutical Drug Manufacturing
What are the Market Opportunities?
. Increasing R&D Spending of Biopharmaceutical Companies
. Future Perspective in Oncology Industry
Why you Should buy this Report?
Apart from market estimation and forecast to 2031 the report covers below mentioned important factors to offer in-depth analysis of cancer biologics industry
. SWOT Analysis
. Porter’s Five Forces Model
. European Oncology Market Trends
. Global Oncology Spending, 2016 - 2031
. Disease Prevalence and Incidence in Europe by Country
. EMA Approved Biologics in Oncology
. Biosimilars and R&D Biologics in Development
This report includes data analysis and invaluable insight into how COVID-19 will affect your industry. Access this report today.
To access the data contained in this document please email
What are the Leading Companies Operating in the Market?
. AbbVie Inc
. F.Hoffman La Roche
. GlaxoSmithKline
. Eli Lilly and Company
. Amgen
. Johnson & Johnson
. Merck & Co.
. Pfizer
Market Segmentation and Scope
Cancer Biologics Market by Treatment
. Chemotherapy
. Targeted Therapy
. Immunotherapy
. Hormonal Therapy
. Others
Cancer Biologics Market by Indication
. Breast cancer
. Cervical cancer
. Colon and rectal cancer
. Gastric cancer
. Lung cancer
. Ovarian cancer
. Renal cell cancer
. Melanoma
Cancer Biologics Market by Biologic Drug
. Bevacizumab
. Trastuzumab
. Trastuzumab emtansine
. Pertuzumab
. Rituximab
. Cetuximab
. Panitumumab
. Ramucirumab
. Necitumumab
. Pembrolizumab
. Atezolizumab
. Durvalumab
. Nivolumab
. Ipilimumab
Cancer Biologics Market by End User
. Hospitals
. Specialty Clinics
. Cancer and Radiation Therapy Centers
Europe Cancer Biologics Market
. UK Cancer Biologics Market
. Germany Cancer Biologics Market
. France Cancer Biologics Market
. Italy Cancer Biologics Market
. Spain Cancer Biologics Market
. Portugal Cancer Biologics Market
. Poland Cancer Biologics Market
. Hungary Cancer Biologics Market
. Czech Republic Cancer Biologics Market
. Slovakia Cancer Biologics Market
. Slovenia Cancer Biologics Market
. Romania Cancer Biologics Market
. Bulgaria Cancer Biologics Market
. Croatia Cancer Biologics Market
. Baltic States Cancer Biologics Market
. Serbia Cancer Biologics Market

Read the full report:

About Reportlinker
ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.


CONTACT: Clare: US: (339)-368-6001 Intl: +1 339-368-6001